Risk vs Benefit in Diabetes Pharmacotherapy: a Rational Approach to Choosing Pharmacotherapy in Type 2 Diabetes

被引：0
|
作者：
Mary Elizabeth Cox
Mark N. Feinglos
机构：
[1] Medical Clinic of North Texas,
[2] Duke University Medical Center,undefined
来源：
Current Diabetes Reports | 2013年 / 13卷
关键词：
Type 2 diabetes; Pharmacotherapy; Metformin; Sulfonylurea; Pioglitazone; Dipeptidyl peptidase-4 inhibitor; Glucagon-like-peptide-1 receptor agonist; Insulin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Type 2 diabetes now affects more than 1 in 10 US adults and is a leading cause of morbidity, mortality, and healthcare expense. There are increasing numbers of available pharmacotherapies, with established agents as well as newer drugs developed from hormones in the incretin pathway, among others. New data are accumulating continuously with respect to potential benefits of both long-standing and new agents, as well as risks identified through post-marketing surveillance. Here we review the commonly prescribed pharmacotherapy options with attention to recently published information and provide a rational approach to choice of therapy.
引用
收藏
页码：319 / 328
页数：9
相关论文
共 50 条
  • [31] The latest pharmacotherapy options for type 1 diabetes
    Ludvigsson, Johnny
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (01) : 37 - 49
  • [32] Current trends in the pharmacotherapy of type 2 diabetes mellitus.
    Kovelman, IR
    Tochilkin, AI
    Belayeva, NF
    Gorodetskii, VK
    Knyazhev, VA
    Tkachenko, CB
    Semenov, LL
    Semenova, NV
    VOPROSY MEDITSINSKOI KHIMII, 2002, 48 (04): : 337 - 352
  • [33] Key considerations in pharmacotherapy for type 2 diabetes mellitus: a multiple target organ approach
    Cornell, S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (03) : 254 - 259
  • [34] Effect of Drugs Used in Pharmacotherapy of Type 2 Diabetes on Bone Density and Risk of Bone Fractures
    Wikarek, Agnieszka
    Grabarczyk, Malgorzata
    Klimek, Katarzyna
    Janoska-Gawronska, Agata
    Suchodolska, Magdalena
    Holecki, Michal
    MEDICINA-LITHUANIA, 2024, 60 (03):
  • [35] Impact of CV Mortality Risk Perception on Patient Preferences for Type 2 Diabetes Mellitus Pharmacotherapy
    Lam, Amanda
    Ozdemir, Semra
    Verghese, Naina
    Baid, Drishti
    Ganguly, Sonali
    Lee, Phong Ching
    Lim, Adoree Y. Y.
    Zhu, Ling
    Finkelstein, Eric
    Goh, Su-Yen
    CIRCULATION, 2019, 140
  • [36] Type 2 diabetes mellitus and cardiovascular risk; what the pharmacotherapy can change through the epigenetics
    Andreeva-Gateva, Pavlina A.
    Mihaleva, Ivelina D.
    Dimova, Ivanka I.
    POSTGRADUATE MEDICINE, 2020, 132 (02) : 109 - 125
  • [37] Differential adoption of pharmacotherapy recommendations for type 2 diabetes by generalists and specialists
    Pugh, MJV
    Anderson, J
    Pogach, LM
    Berlowitz, DR
    MEDICAL CARE RESEARCH AND REVIEW, 2003, 60 (02) : 178 - 200
  • [38] Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?
    Abdul-Ghani, Muhammad
    DeFronzo, Ralph A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (16) : 2113 - 2125
  • [39] Pharmacotherapy of Type 2 Diabetes Mellitus: An Update on Drug–Drug Interactions
    Muhammad Amin
    Naeti Suksomboon
    Drug Safety, 2014, 37 : 903 - 919
  • [40] Predictors of non-adherence to pharmacotherapy in patients with type 2 diabetes
    Anan S. Jarab
    Reham Almrayat
    Salam Alqudah
    Ekbal Thehairat
    Tareq L. Mukattash
    Maher Khdour
    Sharrel Pinto
    International Journal of Clinical Pharmacy, 2014, 36 : 725 - 733
12345